A Phase 2 interventional study of 25 mg Omecamtiv Mecarbil and Placebo in Heart Failure With Reduced Ejection Fraction, sponsored by Cytokinetics. Completed at 32 sites in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-07-27.
Sponsored by Cytokinetics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing omecamtiv mecarbil in Heart Failure — 1 open to participants now, 1 under way, 1 of them phase 3. omecamtiv mecarbil · Heart Failure.
Among the 14 studies testing omecamtiv mecarbil in Heart Failure, this one is the 6th largest by enrollment, is the only one that started in 2016, is one of 7 in phase 2, and was the 10th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →1 of the 14 studies testing omecamtiv mecarbil in Heart Failure is open now, in 10 countries. Recruiting first, the newest first:
Cytokinetics · Sites in United States, Canada, China and 7 more countries
Ages 18–85
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 20 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2016.
This study's enrollment of 81 is close to the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 48 across the 14 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 14 have an industry lead sponsor. The 1 most frequent:
Cytokinetics is the lead sponsor of 41 studies on the registry; 3 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 7 (64%) have results posted.
15 studies in Heart Failure by Cytokinetics: 2 open now, 2 under way, 1 of them phase 3. Of 11 finished, 8 (73%) have results posted.
Among the 15 studies in Heart Failure by Cytokinetics, this one is the 6th largest by enrollment, is the only one that started in 2016, is one of 8 in phase 2, and was the 10th registered.
Cytokinetics’s Heart Failure studies by the year they started, since 2005.
1 of the studies testing omecamtiv mecarbil in Heart Failure that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing omecamtiv mecarbil in Heart Failure, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Cytokinetics’s 15 in Heart Failure:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was conducted by Amgen as the IND holder, with Cytokinetics as a collaborator. Due to the termination of the collaboration agreement between Amgen and Cytokinetics in May 2021 and subsequent transfer of the omecamtiv mecarbil IND from Amgen to Cytokinetics, Cytokinetics is now listed as the sponsor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive placebo BID.
Drug: 25 mg Omecamtiv Mecarbil
Participants will receive 25 mg omecamtiv mecarbil BID.
Drug: Placebo
Participants will receive omecamtiv mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 37.5 mg BID after Week 4 or Week 8, based on Week 2 PK.
Drug: 25 mg Omecamtiv Mecarbil · Drug: 37.5 mg Omecamtiv Mecarbil
Participants will receive Omecamtiv Mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 50 mg BID after Week 4 or Week 8, based on Week 2 PK.
Drug: 25 mg Omecamtiv Mecarbil · Drug: 50 mg Omecamtiv Mecarbil
oral tablet
oral tablet
oral tablet
oral tablet
Pharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over Time
Time frame: Before morning dose on Week 2 (Day 15), Week 4 (Day 28), Week 12 (Day 84), Week 16 (Day 112)
PK: Area Under the Curve Until 8 Hours After Morning Dose at Week 8 (AUC0-8)
Time frame: Week 8 (Day 56) at predose, at 2 hours ±30 minutes; 4 hours ±30 minutes; 6 hours ±30 minutes; 8 hours ±30 minutes after morning dose
Change From Baseline at Week 16 in Systolic Ejection Time (SET)
LS mean was from the repeated measures model, which included treatment group, stratification factor (from IVRS), scheduled visit, baseline value, and the interaction of treatment group with scheduled visit as covariates.
Time frame: Baseline, Week 16 (Day 112)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) is defined as any untoward medical occurrence. Serious AEs are defined as AEs that meets at least 1 of the following serious criteria: fatal, life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, other medically important serious event. AEs are graded as: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. TEAEs are defined as events occurring after the first dose of study drug.
Time frame: From first dose of study drug up to Week 20 (Day 140 + 3 days)
Participants were enrolled at 31 research centers in Japan from 14 April 2016 to 16 December 2016.
| Milestone | Placebo BID | Omecamtiv Mecarbil 25 mg BID | Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose | Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose |
|---|---|---|---|---|
| Started | 21 | 21 | 19 | 20 |
| Completed | 21 | 20 | 19 | 20 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 |
| ng/mL | Omecamtiv Mecarbil 25 mg BID | Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose | Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose |
|---|---|---|---|
| Week 2 | 239 ± 106 | 179 ± 77.1 | 208 ± 61.6 |
| Week 4 | 222 ± 63.5 | 196 ± 44 | 209 ± 61.9 |
| Week 12 | 217 ± 66.1 | 228 ± 56.9 | 282 ± 120 |
| Week 16 | 206 ± 84.5 | 244 ± 67.7 | 292 ± 118 |
| hr*ng/mL | Omecamtiv Mecarbil 25 mg BID | Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose | Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose |
|---|---|---|---|
| PK: Area Under the Curve Until 8 Hours After Morning Dose at Week 8 (AUC0-8) | 1850 ± 563 | 1850 ± 383 | 2360 ± 465 |
LS mean was from the repeated measures model, which included treatment group, stratification factor (from IVRS), scheduled visit, baseline value, and the interaction of treatment group with scheduled visit as covariates.
| msec | Placebo BID | Omecamtiv Mecarbil 25 mg BID | Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose | Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose |
|---|---|---|---|---|
| Change From Baseline at Week 16 in Systolic Ejection Time (SET) | -1.7 ± 4.7 | 20.5 ± 4.9 | 27.6 ± 5.4 | 23.8 ± 5.2 |
An adverse event (AE) is defined as any untoward medical occurrence. Serious AEs are defined as AEs that meets at least 1 of the following serious criteria: fatal, life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, other medically important serious event. AEs are graded as: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. TEAEs are defined as events occurring after the first dose of study drug.
| Participants | Placebo BID | Omecamtiv Mecarbil 25 mg BID | Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose | Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose |
|---|---|---|---|---|
| All TEAEs | 14 | 10 | 10 | 12 |
| Grade >= 2 TEAEs | 10 | 6 | 6 | 7 |
| Grade >= 3 TEAEs | 3 | 4 | 1 | 2 |
| Grade >= 4 TEAEs | 0 | 1 | 0 | 0 |
| Serious AEs | 3 | 4 | 1 | 3 |
| TEAEs Leading to Withdrawal of Study Drug | 0 | 2 | 1 | 0 |
| Fata Adverse Events | 0 | 1 | 0 | 0 |
Collected over From first dose of study drug up to Week 20 (Day 140 + 3 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo BID | 0/21 (0%) | 3/21 (14.3%) | 10/21 (47.6%) |
| Omecamtiv Mecarbil 25 mg BID | 1/21 (4.8%) | 4/21 (19%) | 8/21 (38.1%) |
| Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose | 0/19 (0%) | 1/19 (5.3%) | 10/19 (52.6%) |
| Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose | 0/20 (0%) | 3/20 (15%) | 11/20 (55%) |
| Event | Placebo BID | Omecamtiv Mecarbil 25 mg BID | Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose | Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/21 | 0/21 | 1/19 | 0/20 |
| Angina pectorisCardiac disorders | 0/21 | 0/21 | 0/19 | 1/20 |
| Cardiac failureCardiac disorders | 1/21 | 1/21 | 0/19 | 1/20 |
| Cardiac failure chronicCardiac disorders | 0/21 | 1/21 | 0/19 | 1/20 |
| Vascular stent restenosisGeneral disorders | 0/21 | 0/21 | 0/19 | 1/20 |
| Cardiac failure congestiveCardiac disorders | 0/21 | 1/21 | 0/19 | 0/20 |
| Cardiac ventricular thrombosisCardiac disorders | 1/21 | 0/21 | 0/19 | 0/20 |
| Cardio-respiratory arrestCardiac disorders | 0/21 | 1/21 | 0/19 | 0/20 |
| Ventricular fibrillationCardiac disorders | 0/21 | 1/21 | 0/19 | 0/20 |
| Hepatic function abnormalHepatobiliary disorders | 0/21 | 1/21 | 0/19 | 0/20 |
| Event | Placebo BID | Omecamtiv Mecarbil 25 mg BID | Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose | Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose |
|---|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 4/21 | 1/21 | 4/19 | 4/20 |
| PeriodontitisInfections and infestations | 0/21 | 1/21 | 2/19 | 0/20 |
| HypotensionVascular disorders | 0/21 | 0/21 | 2/19 | 0/20 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/21 | 0/21 | 0/19 | 2/20 |
| DizzinessNervous system disorders | 1/21 | 1/21 | 0/19 | 2/20 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/21 | 2/21 | 0/19 | 0/20 |
| InfluenzaInfections and infestations | 1/21 | 2/21 | 0/19 | 0/20 |
| DehydrationMetabolism and nutrition disorders | 0/21 | 2/21 | 0/19 | 0/20 |
| DermatitisSkin and subcutaneous tissue disorders | 0/21 | 2/21 | 0/19 | 0/20 |
| BradycardiaCardiac disorders | 0/21 | 0/21 | 1/19 | 0/20 |
| Age, Continuous(years) | Placebo BID | Omecamtiv Mecarbil 25 mg BID | Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose | Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose | Total |
|---|---|---|---|---|---|
| Mean | 64.6 ± 11.5 | 66.9 ± 10.3 | 63.6 ± 10.8 | 66.5 ± 12.2 | 65.4 ± 11.1 |
| Sex: Female, Male(Participants) | Placebo BID | Omecamtiv Mecarbil 25 mg BID | Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose | Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose | Total |
|---|---|---|---|---|---|
| Female | 9 | 3 | 0 | 1 | 13 |
| Male | 12 | 18 | 19 | 19 | 68 |
| Race/Ethnicity, Customized(participants) | Placebo BID | Omecamtiv Mecarbil 25 mg BID | Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose | Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose | Total |
|---|---|---|---|---|---|
| Asian | 21 | 21 | 19 | 20 | 81 |
| Other | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Placebo BID | Omecamtiv Mecarbil 25 mg BID | Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose | Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose | Total |
|---|---|---|---|---|---|
| Japanese | 21 | 21 | 19 | 20 | 81 |
| Other | 0 | 0 | 0 | 0 | 0 |
| Atrial Fibrillation/Flutter at Randomization(participants) | Placebo BID | Omecamtiv Mecarbil 25 mg BID | Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose | Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose | Total |
|---|---|---|---|---|---|
| Present | 4 | 4 | 3 | 4 | 15 |
| Absent | 17 | 17 | 16 | 16 | 66 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2016 to primary completion in Apr 2017, 11 months.
Results were first posted in Jan 2020, 2 years 9 months after primary completion. A results delay was requested in Feb 2018.
Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 11 months is below that.
Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omecamtiv mecarbil